Navigation Links
HRA Reports Growing Number of Oncologists Following Clinical Pathways, Yet Standard Treatment Algorithms Exclude Some Cancer Drugs

PARSIPPANY, N.J. (PRWEB) February 12, 2015

A growing number of oncologists are following standard, scientifically proven treatment algorithms called clinical pathways, tools designed to help oncologists make decisions based on best practices rather than habit or other factors. While the pathways leave room for individualized care, they also threaten to leave some cancer drugs by the wayside in the future, according to a new study from HRA – Healthcare Research & Analytics, a leading consultative healthcare market research practice.

“Since these treatment pathways are designed to offer the best course of treatment for 80% to 90% of patients with the corresponding form of cancer, drugs that aren’t on pathways will be challenged to gain market share,” said Denis Goldenberg, vice president of oncology market research at HRA. The pathways are developed for specific cancer diagnoses based on the availability of supporting data for treating a particular type of cancer, but rarely in a head-to-head fashion. It is conceivable that an otherwise effective drug could face market access issues due to exclusion from these clinical pathways if its development did not account for these important criteria required by pathway developers.

According to the new HRA study, “Evidence-Based Oncology: Future of Incentive-Driven Pathway Adherence,” as the use of clinical pathways increases, drug manufacturers will be more pressed than ever to justify inclusion of their cancer drugs in one or more pathways. More insurance carriers are requiring and encouraging use of clinical pathways – including offering financial rewards for staying with a pathway – to improve patient outcomes and lower costs.

“It's our belief that pathways programs save on the order of 10% to 15% of the drug bill, something like that,” said one of the national payers interviewed in the study, an unnamed medical director. This estimate doesn’t take into consideration the savings from use of biosimilars over use of their branded counterparts – another reason for instituting such pathways.

The study shows that oncologists and insurance carriers are aligned and working closely together on pathways. Three-fourths of the oncologists surveyed said they believe insurance companies are motivated by cost savings and the goal of standardizing patient care for better outcomes.

HRA used multiple sources to develop the study, including interviews with oncologists and regional and national payers such as Aetna, Humana, Anthem, Blue Cross Blue Shield, and Priority Health.

Visit to learn more about HRA and read additional insights about the growing use of clinical pathways in oncology, payer rewards for pathway adherence and implications for drug manufacturers provided by “Evidence-Based Oncology: Future of Incentive-Driven Pathway Adherence.”

About HRA – Healthcare Research & Analytics
HRA – Healthcare Research & Analytics is a consultative healthcare market research practice leveraging a flexible spectrum of solutions to support decision making and strategy development across healthcare channels with expertise in health systems. HRA’s team of highly experienced market researchers combines deep domain expertise in healthcare, science, business and statistics with a passion for uncovering insights. HRA’s portfolio of offerings encompasses quantitative and qualitative, custom and syndicated market research services to support the business needs of the pharmaceutical, biotech, and medical device markets – including stakeholder identification and management as well as field force effectiveness evaluation and sales training optimization. HRA’s people and its products provide the healthcare market with actionable intelligence – facilitating better business decisions. HRA is a subsidiary of Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH), which combines the power of an established network of publications and websites with the customer service focus and customization capabilities of a boutique firm. To learn more about HRA or MJH, please visit or


Media Contacts for HRA
Becky Taylor, 609-240-6886 or becky(at)btaylorpa(dot)com
Kevin M. Kelly, 973-240-1200 or kkelly(at)hraresearch(dot)com

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmAthene Reports Year-End 2012 Financial And Operational Results
2. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
4. Global Bio-implants Market 2012-2016 New Research Report Now Available at
5. Neogen reports 27% increase in quarterly net income
6. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
7. Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
8. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
9. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at
10. Global Biomaterial Market: To Grow at a 15% CAGR Says New Research Report at
11. GeneLink Reports 2012 Financial Results
Post Your Comments:
(Date:6/11/2019)... ... June 11, 2019 , ... A ... mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying ... on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
(Date:5/15/2019)... FALLS, Wis. (PRWEB) , ... May 16, 2019 ... ... oil and water mixtures. As a result, food and beverage products rely on ... today, consumers demand more natural sounding label declarations. This paradigm shift triggers food ...
(Date:5/4/2019)... PAULO, Brazil (PRWEB) , ... May 03, 2019 ... ... lecture given by the President of the Dakila Pesquisas Association, the scientist and ... the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research ...
Breaking Biology Technology:
(Date:6/11/2019)... ... , ... Improved Pharma LLC announces the publication of “Predictive and Accelerated Formulation ... was published online on April 29th, 2019. The authors are Stephen R. Byrn ... Purdue University. , The article is the most recent addition to a theme dedicated ...
(Date:6/4/2019)... ... June 04, 2019 , ... ... appointment of Susan Murphy as the new President of Molecular Devices, replacing Greg ... Devices’ parent company, Danaher Corporation. , Since joining Molecular Devices in a scientific ...
(Date:6/1/2019)... ... May 31, 2019 , ... ... Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. ... securing value-added institutional investors who bring significant financial and business resources to bear ...
Breaking Biology News(10 mins):